GlassScriptPhysician profile
Maribeth W Gambill
NPI 1144334863
$4,826.41
in general payments reported to CMS, 2019-2025
24 companies · $516 in 2025
The $516 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,373 · 2022: $1,419 · 2023: $1,155 · 2024: $362 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993 · Gift: $40.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.64 |
| Gift | $40.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,420.23 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $949.74 | 2021-2024 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $364.95 | 2021-2023 | |
| Gilead Sciences, INC. | $306.32 | 2022-2025 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $263.04 | 2021-2023 | Entyvio |
| Merck Sharp & Dohme LLC | $230.06 | 2021-2024 | Dificid |
| Revance Therapeutics, INC. | $175.18 | 2024 | Daxxify |
| Evoke Pharma, INC. | $174.72 | 2021-2022 | |
| Madrigal Pharmaceuticals | $123.19 | 2025 | Rezdiffra |
| Ardelyx, INC. | $122.88 | 2022-2023 | Ibsrela |
| Abbott Laboratories | $108.40 | 2023 | Freestyle Libre 3 |
| Braintree Laboratories, INC. | $84.78 | 2021-2023 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $78.81 | 2021-2022 | |
| Viiv Healthcare Company | $75.01 | 2021 | |
| Aimmune Therapeutics, INC. | $54.66 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $50.71 | 2025 | Puraply Wound Matrix |
| Janssen Biotech, INC. | $48.30 | 2023-2024 | Stelara |
| Redhill Biopharma INC. | $39.63 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $39.37 | 2023-2024 | Dupixent |
| Davol INC. | $31.09 | 2025 | Phasix Mesh |
| W. L. Gore & Associates, INC. | $30.32 | 2024 | Gore Enform Preperitoneal Biomaterial |
| Genzyme Corporation | $24.74 | 2023 | |
| Amgen INC. | $17.09 | 2023 | Amjevita |
| Lilly USA, LLC | $13.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribeth Gambill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.